PCVX: Material agreement · New financial obligation · Other company developments

Item 1.01 Entry into a Material Definitive Agreement. On October 9, 2026, Vaxcyte, Inc. (“ Vaxcyte ”) consummated the sale and issuance of $575,000,000 aggregate principal amount of its 1.50% Convertible Senior Notes due 2032 (the “ Notes ”) to certain underwriters (the “ Debt Offering ”). The Notes were issued pursuant to, and are governed by, an indenture (the “ Base Indenture ”), dated as of October 9, 2026, between Vaxcyte and U.S. Bank Trust Company, National Association, as trustee (the “ Trustee ”), as supplemented by a First Supplemental Indenture (the “ Supplemental Indenture ,” and the Base Indenture, as supplemented by the Supplemental Indenture, the “ Indenture ”), dated as of October 9, 2026, between Vaxcyte and the Trustee. The Notes are senior, unsecured obligations and will accrue interest at a rate of 1.50% per annum, payable semi-annually in arrears on April 15 and October 15 of each year, beginning on April 15, 2027. The Notes will mature on October 15, 2032 unless earlier repurchased, redeemed or converted. Before July 15, 2032, noteholders will have the right to convert their Notes only upon the occurrence of certain events. From and after July 15, 2032, noteholders may convert their Notes at any time at their election until the close of business on the second scheduled trading day immediately before the maturity date. Vaxcyte will settle conversions by paying or delivering, as applicable, cash, shares of its common stock, par value $0.001 per share (“ Common Stock ”) or a combination of cash and shares of Common Stock, at its election. The initial conversion rate is 11.1607 shares of Common Stock per $1,000 principal amount of Notes, which represents an initial conversion price of approximately $89.60 per share of Common Stock. The conversion rate